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OBJECTIVES We sought to assess the effect of rosiglitazone on markers of endothelial cell activation and
acute-phase reactants in non-diabetic patients with coronary artery disease (CAD).
BACKGROUND Inflammation plays a key role in all stages of atherosclerosis and in the genesis of acute
coronary syndromes. Rosiglitazone, a peroxisome proliferator-activated receptor gamma
agonist, is used in the treatment of type 2 diabetes mellitus, and previous data suggest that it
may have anti-inflammatory effects on atherosclerosis.
METHODS Patients with stable, angiographically documented CAD without diabetes mellitus were
investigated. Patients were randomized in a double-blind manner to receive treatment with
placebo or rosiglitazone (4 mg/day for 8 weeks followed by 8 mg/day for 4 weeks) for 12 weeks.
Eighty-four patients completed the study. Fasting glucose, insulin, lipid profile, markers of
endothelial activation, and inflammatory markers were measured at baseline and after 12 weeks.
RESULTS Rosiglitazone treatment resulted in a significant reduction in E-selectin (p  0.03), von
Willebrand factor (p  0.007), C-reactive protein (p  0.001), fibrinogen (p  0.003) and
the homeostasis model of insulin resistance index (p  0.02), compared with placebo.
Significant elevations in low-density lipoprotein and triglyceride levels were observed in the
rosiglitazone group (p  0.01). Within the rosiglitazone-treated group, reductions in
C-reactive protein and von Willebrand factor were significantly correlated with a reduction in
insulin resistance.
CONCLUSIONS Rosiglitazone significantly reduces markers of endothelial cell activation and levels of
acute-phase reactants in CAD patients without diabetes. Potential underlying mechanisms
include insulin sensitization and direct modification of transcription within the vessel
wall. (J Am Coll Cardiol 2003;42:1757–63) © 2003 by the American College of
Cardiology Foundation
Inflammation is thought to play a key role in all stages of
atherosclerosis and in the genesis of acute coronary syn-
dromes (1). A key step in the formation and maturation of
atherosclerotic plaques is endothelial cell activation (2). This
is characterized by expression of cell adhesion molecules
(CAMs; allowing adhesion and transmigration of leuko-
cytes to the endothelium), a prothrombotic state, and
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impaired vascular reactivity (2). Elevated plasma levels of
several markers of the inflammatory cascade have been
shown to predict a future risk of cardiovascular events,
including the acute-phase reactants, C-reactive protein
(CRP), and fibrinogen (3). Peroxisome proliferator-
activated receptor gamma (PPAR-gamma), a member of
the nuclear receptor superfamily of ligand-activated tran-
scription factors, is highly expressed in atherosclerotic
plaques (4,5). The agonists of this receptor in clinical use are
the thiazolidinediones rosiglitazone (Avandia) and pioglita-
zone (Actos). These agents have insulin-sensitizing actions
and are used in the treatment of type 2 diabetes. Accumu-
lating evidence suggests that PPAR-gamma agonists may
have inhibitory effects on inflammatory processes in athero-
sclerotic plaques through indirect (insulin-sensitizing) and
direct mechanisms.
Insulin resistance and hyperinsulinemia represent major
risk factors for atherosclerotic disease (6). Thiazolidinedio-
nes both reduce insulin resistance and ameliorate the pro-
atherogenic components of the insulin resistance syndrome,
including dyslipidemia, the procoagulant state, and endo-
thelial dysfunction (7–9). Insulin-resistant states are also
associated with chronic, subclinical inflammation, and this
may have a pathogenic role in atherogenesis and atheroscle-
rotic disease complications (10). This association suggests
that insulin sensitization may have an anti-inflammatory
effect, and there are data to support this concept. Clinical
studies, in obese or diabetic subjects without overt athero-
sclerosis, have shown that troglitazone and rosiglitazone can
reduce levels of inflammatory markers (11–13).
Recent in vitro data suggest that PPAR-gamma agonists
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may also act directly on the vessel wall and modify the
transcription of pro-inflammatory genes within atheroscle-
rotic plaques (14). One important molecular target of
PPAR-gamma agonism is the transcription factor called
nuclear factor-kappa-B (NF-kappa-B), which controls the
synthesis of many of these pro-inflammatory genes (15).
Although data from some animal studies suggest that
PPAR-gamma agonists may reverse endothelial dysfunction
and reduce markers of vascular inflammation (16–18), other
in vitro studies failed to show any effect of PPAR-gamma
agonists on adhesion molecule expression (19). Early studies
showed that PPAR-gamma agonists may have a pro-
atherogenic effect by upregulating the expression of the
scavenger receptor CD36 in macrophages, which facilitates
the uptake of oxidized low-density lipoprotein (LDL) (20).
Recent data suggest that PPAR-gamma may actually have a
dual action on cholesterol transport in macrophages as they
also promote cholesterol efflux through induction of the
ABCA1 transport protein, resulting in net lipid removal
(21–23). Indeed, thiazolidinediones have consistently been
shown to reduce atherosclerotic lesion formation in mouse
models of atherosclerosis (24–27). To date, no clinical
studies have examined the effects of PPAR-gamma agonists
on inflammatory markers or endothelial cell activation in
patients with atherosclerotic disease.
The aim of this study was to assess the effect of rosigli-
tazone on markers of endothelial cell activation (E-selectin
and von Willebrand factor [vWF]) and acute-phase reac-
tants (CRP and fibrinogen) in non-diabetic patients with
coronary artery disease (CAD).
METHODS
Study patients. Consecutive patients with stable CAD
were recruited from outpatient clinics to our institution.
Inclusion criteria were angiographically documented CAD
(50% lumen diameter reduction of at least one major
coronary artery according to 2 independent observers) and
age 75 years. Patients with any of the following were
excluded: a previous clinical diagnosis of diabetes mellitus,
history of acute coronary syndrome or revascularization in
the previous three months, rest angina, cardiac failure, any
change in cardiovascular medication during the preceding
six weeks, malignant or hematologic disease, baseline ala-
nine transaminase greater than two times the upper limit
of normal, or women of child-bearing potential. The
study was approved by the Local Research Ethics Com-
mittee, and all subjects gave written, informed consent
before enrollment.
Study design. Subjects were randomized in a double-blind
manner to receive placebo or rosiglitazone for 12 weeks.
They received single-dose placebo or rosiglitazone 4 mg/day
for the initial eight weeks, and the doses were doubled for
the final four weeks. All other medications remained un-
changed during the study. Rosiglitazone and matching
placebo tablets were supplied by GlaxoSmithKline (U.K.).
Study protocol. Height, weight, and waist and hip circum-
ferences were measured at baseline. Subjects had fasting
blood samples collected in the morning for measurement of
electrolytes, liver transaminases, lipid profile, insulin, glu-
cose, markers of endothelial cell activation (E-selectin and
vWF), and acute-phase reactants (CRP and fibrinogen). All
measurements were repeated after 12 weeks of therapy.
Biochemical parameters. Electrolytes, glucose, total and
high-density lipoprotein (HDL) cholesterol, and triglycer-
ides were measured using a Beckman Coulter Synchron LX
20 analyzer (Beckman Coulter Inc., California). The LDL
cholesterol was calculated according to the Friedwald equa-
tion (28). Serum insulin was measured by immunoassay
(Elecsys, Roche Diagnostics, Mannheim, Germany). The
homeostasis model of insulin resistance index (HOMA-R)
was used as a measure of insulin resistance, where
HOMA-R is calculated as fasting serum insulin (U/ml)
fasting plasma glucose (mmol/l)/22.5 (29).
E-selectin, vWF, fibrinogen, and CRP measurements.
E-selectin and vWF were measured by means of ELISA
methods (R&D Systems [Abington, UK] and Dako Ltd.
[Ely, UK], respectively). Fibrinogen was determined by the
Clauss method. The CRP concentrations were measured by
means of a high-sensitivity Immulite ELISA immunoassay
(DPC Ltd., Gwynedd, UK).
Statistical analysis. Results are presented as the mean 
SD for continuous normally distributed variables, median
(interquartile range) for continuous non-normally distrib-
uted data (CRP), and percentages for categorical data. The
CRP levels were logarithmically (log10) transformed before
being used in a comparative analysis. Comparisons between
two mean values were performed by use of the unpaired,
two-tailed t test. Differences between the repeated measure-
ments of continuous variables were assessed by means of
analysis of variance for repeated measurements. Categorical
data were analyzed by means of the Fisher exact test.
Correlations between continuous variables were assessed
using the Pearson correlation coefficient. A p value 0.05
was considered to be statistically significant, and all reported
p values are two-sided. Statistical analysis was performed
with SPSS version 10.01 software.
Abbreviations and Acronyms
CAD  coronary artery disease
CAM  cell adhesion molecule
CRP  C-reactive protein
HDL  high-density lipoprotein
HOMA-R  homeostasis model of insulin resistance
index
LDL  low-density lipoprotein
NF-kappa-B  nuclear factor-kappa-B
PPAR-gamma  peroxisome proliferator-activated
receptor-gamma
vWF  von Willebrand factor
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RESULTS
Baseline characteristics and safety profile. Ninety-two
patients were enrolled in the study, and 46 were assigned to
each treatment. Two subjects were unwilling to attend for
follow-up, and two subjects assigned to rosiglitazone with-
drew due to side effects (dizziness and nausea, respectively).
Four patients with baseline fasting plasma glucose 126
mg/dl (diagnostic criteria for diabetes mellitus) were ex-
cluded. Hence, the data on 84 subjects in total were
analyzed. There were no other adverse events or biochem-
ical side effects, in particular, any elevation in liver transami-
nases. Baseline clinical characteristics were similar in both
groups (Table 1).
Comparison between treatment groups. METABOLIC PA-
RAMETERS. Rosiglitazone treatment significantly reduced
HOMA-R compared with placebo. In the rosiglitazone
group, HOMA-R decreased from 2.45  1.75 to 2.01 
1.78, whereas in the placebo group, there was a slight rise
from 2.52  1.43 to 2.84  1.59 (p  0.02) (Table 2).
Compared with the placebo group, rosiglitazone treatment
also significantly increased total and LDL cholesterol levels.
In the rosiglitazone group, total cholesterol increased from
169  32 to 186  29 mg/dl, with no significant change in
the placebo group (p  0.001) (Table 2). In the rosiglita-
zone group, LDL cholesterol increased from 102  27 to
113  27 mg/dl, with no significant change in the placebo
group (p  0.008) (Table 2). The HDL cholesterol levels
showed no significant change in either group (Table 2).
Rosiglitazone treatment significantly increased triglyceride
levels, compared with the placebo group. Triglyceride levels
increased from 108 54 to 130 63 mg/dl, whereas in the
placebo group, there was no significant change (p  0.005)
(Table 2). There were no significant treatment effects on
anthropometric measures (data not shown).
E-SELECTIN, VWF, FIBRINOGEN, AND CRP LEVELS. As
shown in Table 3, baseline levels of E-selectin, vWF,
fibrinogen, and CRP were similar in the rosiglitazone and
placebo groups. After 12 weeks of treatment, patients who
received rosiglitazone showed modest but significant de-
creases in E-selectin and vWF levels (p  0.03 and p 
0.007, respectively) compared with the placebo group (Ta-
ble 3, Fig. 1). In the rosiglitazone group, E-selectin de-
Table 1. Baseline Characteristics
Placebo
(n  44)
Rosiglitazone
(n  40)
Male 35 36
Female 9 4
Age (yrs) 63  7.2 61.4  7.0
BMI (kg/m2) 27.29  3.78 26.59  3.25
Fasting glucose (mg/dl) 102  7 102  9
Fasting insulin (U/ml) 9.64  5.21 9.08  6.05
HOMA-R 2.52  1.43 2.45  1.75
Total cholesterol (mg/dl) 173  40 169  32
LDL cholesterol (mg/dl) 100  33 102  27
HDL cholesterol (mg/dl) 47  11 46  10
Triglycerides (mg/dl) 135  86 108  54
IFG (fasting glucose 110 mg/dl) 7 (16%) 9 (22%)
Current smokers 6 (14%) 5 (12%)
Hypertension 17 (39%) 21 (52%)
Aspirin 44 (100%) 40 (100%)
Beta-blocker 16 (36%) 21 (52%)
Calcium antagonist 15 (34%) 11 (27%)
ACE inhibitor/angiotensin II antagonist 17 (39%) 21 (52%)
Long-acting nitrate 7 (16%) 5 (12%)
Statin therapy 42 (96%) 38 (95%)
Previous coronary revascularization 37 (84%) 37 (92%)
Previous MI 21 (48%) 19 (47%)
Data are presented as the number (%) of subjects or mean value  SD. There were
no significant differences between the groups.
ACE  angiotensin-converting enzyme; BMI  body mass index; HDL 
high-density lipoprotein; HOMA-R homeostasis model of insulin resistance index;
IFG impaired fasting glycemia; LDL low-density lipoprotein; MI myocardial
infarction.
Table 2. Metabolic Variables at Baseline and After 12 Weeks of
Treatment With Placebo or Rosiglitazone
Placebo
(n  44)
Rosiglitazone
(n  40)
Glucose (mg/dl)
Baseline 102  7 102  9
12 weeks 101  6 99  9
HOMA-R
Baseline 2.52  1.43 2.45  1.75
12 weeks 2.84  1.59 2.01  1.78*
Total cholesterol (mg/dl)
Baseline 173  40 169  32
12 weeks 172  36 186  29†
LDL cholesterol (mg/dl)
Baseline 100  33 102  27
12 weeks 100  27 113  27‡
HDL cholesterol (mg/dl)
Baseline 47  11 46  10
12 weeks 47  10 46  9
Triglycerides (mg/dl)
Baseline 135  86 108  54
12 weeks 132  94 130  63‡
*p  0.05, †p  0.001, ‡p  0.01 by analysis of variance for repeated measurements.
Data are presented as the mean value  SD.
Abbreviations as in Table 1.
Table 3. E-Selectin, von Willebrand Factor, Fibrinogen, and
C-Reactive Protein Levels at Baseline and After 12 Weeks of
Treatment With Placebo or Rosiglitazone
Placebo
(n  44)
Rosiglitazone
(n  40)
E-selectin (ng/ml)
Baseline 48.1  21.2 48.9  16.4
12 weeks 46.5  24.1 43.4  16.0*
vWF (IU/dl)
Baseline 146  54 138  46
12 weeks 156  49 131  43*
Fibrinogen (g/l)
Baseline 3.49  0.68 3.81  1.12
12 weeks 3.58  0.75 3.38  0.65†
CRP (mg/l)
Baseline 0.74 (0.41–1.39) 0.56 (0.34–1.02)
12 weeks 0.72 (0.36–1.30) 0.35 (0.26–0.50)†
*p 0.05, †p 0.005 by analysis of variance for repeated measurements. At baseline,
there were no significant differences between the groups. Data are presented as the
mean value  SD or median value (interquartile range).
CRP  C-reactive protein; vWF  von Willebrand factor.
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creased from 48.9 16.4 to 43.4 16.0 ng/ml, whereas the
placebo group showed no change. The vWF level decreased
in the rosiglitazone group (138  46 to 131  43 IU/dl),
whereas the vWF level increased by a similar degree in the
placebo group (146  54 to 156  49 IU/dl).
The rosiglitazone group also showed significantly de-
creased CRP and fibrinogen levels (p  0.001 and p 
0.003, respectively) compared with the placebo group (Ta-
ble 3, Fig. 2). In the rosiglitazone group, the CRP level
decreased from 0.56 (0.34 to 1.02) to 0.35 (0.26 to 0.50)
mg/l, a relative reduction of 37%, whereas the placebo group
showed no change. The fibrinogen level decreased in the
rosiglitazone group (3.81  1.12 to 3.38  0.65 g/l), whereas
the fibrinogen level showed no change in the placebo group.
Within the rosiglitazone-treated group, reductions in
CRP and vWF were significantly correlated with a reduc-
tion in HOMA-R (r  0.37, p  0.02 and r  0.33, p 
0.04, respectively). No significant correlation was observed
between a reduction in fibrinogen or E-selectin and a fall in
HOMA-R (r  0.18 and r  0.12, respectively).
DISCUSSION
The most significant findings from this study are that
rosiglitazone reduced circulating markers of endothelial cell
activation (vWF and E-selectin) and acute-phase reactants
(CRP and fibrinogen) in non-diabetic patients with CAD.
Endothelial cell activation results in a release of the pro-
thrombotic protein vWF from Weibel-Palade bodies and
expression of CAMs, such as E-selectin, which facilitate
entry of circulating monocytes to plaques. The plasma vWF
level has been shown to be a predictor of cardiovascular
Figure 1. Effect of rosiglitazone on E-selectin and von Willebrand factor
levels. Paired results at baseline and after 12 weeks of treatment are shown in
each treatment group. Boxes indicate mean values, and bars represent 95%
confidence intervals. *p  0.05 for the change in the rosiglitazone versus
placebo group.
Figure 2. Effect of rosiglitazone on fibrinogen and log (CRP) levels. Paired
results at baseline and after 12 weeks of treatment are shown in each
treatment group. Boxes indicate mean values, and bars represent 95%
confidence intervals. †p  0.005 for the change in the rosiglitazone versus
placebo group.
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events in patients with atherosclerotic disease (30). Al-
though the pathogenic role of circulating CAMs that have
been shed from the endothelium is unclear, plasma levels of
soluble CAMs have been reported to be significant predic-
tors of clinical outcome in patients with documented CAD
(31,32). Elevated fibrinogen is a risk factor for death or
recurrence of myocardial ischemia in patients with a previ-
ous coronary event, as well as a predictor of accelerated
coronary atherosclerosis (33). An increase in fibrinogen
levels may predispose to an atherothrombotic event through
infiltration of the vessel wall by fibrinogen, rheologic effects
due to increased blood viscosity, increased platelet aggrega-
tion and thrombus formation, and increased fibrin forma-
tion (33). C-reactive protein, produced in the liver in
response to interleukin-6, has emerged as a marker of future
cardiovascular risk among patients with stable and unstable
angina (3). Recent evidence suggests that CRP may have
direct pro-inflammatory effects (34). Data from statin trials
suggest that reducing the inflammatory burden may im-
prove the clinical outcome in atherosclerotic disease, even in
patients with normal cholesterol levels (35). Notably, nearly
all the patients in the present study were receiving long-
term statin therapy, which has been shown to lower median
CRP levels by 14% in CAD patients (36). Even so, we
observed that rosiglitazone-treated patients showed a
marked 37% reduction in median CRP levels after 12 weeks
of therapy. The anti-inflammatory effects of rosiglitazone
observed in our study may have therapeutic benefits, partic-
ularly in the high-risk group of patients with atherosclerotic
disease and type 2 diabetes. It is likely that rosiglitazone
modifies endothelial cell activation and expression of acute-
phase reactants through indirect (metabolic) and direct
actions on the vessel wall.
We studied non-diabetic patients with CAD to investi-
gate the anti-inflammatory effects of rosiglitazone, indepen-
dent of its hypoglycemic action. In our study cohort, the
baseline insulin resistance (HOMA-R) in both the placebo
and rosiglitazone groups was similar and mildly elevated
compared with healthy non-diabetic control subjects (29).
As expected, rosiglitazone treatment resulted in a significant
reduction in insulin resistance compared with placebo. In
the active treatment group, insulin resistance actually fell to
within the normal range reported in epidemiologic studies
(29). Our data also show that in the rosiglitazone-treated
group, a reduction in CRP and vWF correlated closely with
a reduction in insulin resistance. Previous studies have also
shown that in insulin-resistant mice and humans, insulin-
sensitizing agents decrease endothelial cell activation mark-
ers and acute-phase reactants (11–13,37). Therefore, it is
likely that insulin sensitization is one mechanism by which
rosiglitazone reduced inflammatory markers in this study.
Because of logistical constraints related to the repeated
investigation of a relatively large number of patients, insulin
resistance was assessed using HOMA-R rather than more
sensitive euglycemic insulin clamp techniques. Even so, we
were able to demonstrate a significant insulin-sensitizing
effect of rosiglitazone in our non-diabetic cohort of patients.
Our results also showed that rosiglitazone treatment
resulted in modest but significant rises in total and LDL
cholesterol and triglyceride levels, with no effect on HDL
cholesterol levels. These changes are in contrast to the lipid
effects of rosiglitazone reported in most of the studies with
type 2 diabetic patients. Randomized studies have shown
that rosiglitazone treatment results in modest but significant
increases in total, LDL, and HDL cholesterol, with triglyc-
eride levels and the total/HDL cholesterol ratio remaining
unchanged (38,39). However, one small observational study
in type 2 diabetics also reported that rosiglitazone therapy
caused modest increases in total and LDL cholesterol and
triglycerides, with a trend toward decreased HDL choles-
terol (40). Recent data also suggest that the thiazolidinedio-
nes may differ in their effects on lipid metabolism, with
pioglitazone having less LDL cholesterol-raising effects
than rosiglitazone (41). There is no clear mechanistic
explanation for the effects of rosiglitazone on lipid metab-
olism in our non-diabetic patients. Rosiglitazone has been
reported to increase the LDL particle size in diabetic
patients (38). If the same effect was exerted in the non-
diabetic patients investigated in our study, this may result in
a rise in the absolute LDL concentration. Clearly, further
studies are needed to determine the precise mechanisms by
which PPAR-gamma agonists alter lipid metabolism. Re-
gardless of the underlying mechanisms, the potentially
deleterious effect of a rise in LDL cholesterol and triglyc-
eride levels on endothelial cell activation and inflammatory
burden deserves consideration. It is well established that
LDL, after oxidative modification, activates endothelial
cells to cause upregulation of endothelial adhesion mole-
cules, selectins, and release of vWF (42). Hypertriglyceri-
demia has been shown to have a pro-inflammatory effect on
atherosclerosis and enhances adhesion molecule expression
(43). It is therefore possible that elevation of LDL choles-
terol or triglyceride levels might increase endothelial cell
activation and levels of acute-phase reactants. Whether the
modest elevation in mean LDL cholesterol and triglyceride
levels observed in the rosiglitazone group (11% and 20%,
respectively) would have significant pro-inflammatory ef-
fects in vivo is open to debate. In summary, the effects of
rosiglitazone on the lipid profile in our model do not explain
the anti-inflammatory effect observed. Conversely, the ele-
vation in triglyceride and LDL cholesterol levels may have
a pro-inflammatory effect.
A potential mechanism by which rosiglitazone may exert
an anti-inflammatory effect is through modifying transcrip-
tion of pro-atherogenic genes in the vessel wall (14). This
may explain why rosiglitazone reduced endothelial activa-
tion and inflammatory markers in our study population,
despite elevating lipid levels. Previous in vitro studies have
shown that PPAR-gamma agonists modulate transcription
factors such as NF-kappa-B and thereby inhibit synthesis of
pro-atherogenic gene products such as cytokines, chemo-
1761JACC Vol. 42, No. 10, 2003 Sidhu et al.
November 19, 2003:1757–63 Anti-Inflammatory Effects of Rosiglitazone
kines, matrix metalloproteinases, and adhesion molecules
(44). In a study in LDL receptor-deficient mice, Li et al.
(26) observed that rosiglitazone reduced aortic tissue expres-
sion of the cytokine tumor necrosis factor-alpha. This
cytokine stimulates interleukin-6 production by smooth
muscle cells, and interleukin-6 is the main hepatic stimulus
for CRP production (3). In our study, we observed that in
the rosiglitazone group, although a reduction in CRP and
vWF correlated significantly with insulin sensitization, a
reduction in E-selectin and fibrinogen levels did not show
such a correlation. This suggests that insulin sensitization
may not be the sole mechanism by which rosiglitazone
exerted the anti-inflammatory effects observed. The mech-
anisms by which rosiglitazone reduces endothelial cell acti-
vation and levels of acute-phase reactants require further
investigation. In order to assess the direct (vessel wall)
effects of rosiglitazone, independent of metabolic effects,
studies in patients with normal baseline insulin resistance
are needed.
Study limitations. Our study has certain limitations that
merit consideration. Although vWF and E-selectin levels
fell significantly in the rosiglitazone compared with placebo
group, the relative changes were modest (5% and 10%,
respectively), and the biologic significance of these changes
is questionable. Interestingly, statins have been shown to
produce a similar 10% reduction in vWF levels in hyper-
cholesterolemic patients (45). In the present study, addi-
tional indexes of endothelial activation were not measured,
such as vascular cell adhesion molecule-1 or intercellular
adhesion molecule-1 levels and endothelial vasomotor
function.
Conclusions. We have demonstrated that the PPAR-
gamma agonist rosiglitazone reduces markers of endothelial
cell activation, CRP, and fibrinogen levels in non-diabetic
patients with CAD. Potential mechanisms underlying this
anti-inflammatory effect include insulin sensitization and
direct modulation of transcriptional activity in the vessel
wall. Further clinical studies, both in diabetics and non-
diabetics, are warranted to determine whether this anti-
inflammatory action translates into a therapeutic benefit in
atherosclerotic coronary disease.
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